STAT+: Pharmalittle: We’re reading about a U.S. senator probing FDA, BioNTech founders leaving, and much more

The co-founders of BioNTech, a developer of the Covid-19 vaccine, are planning to leave the company to establish a new mRNA-focused enterprise. This transition marks a significant shift for the founders, who have been pivotal in the development of mRNA technology used in vaccines. The details surrounding their departure and the formation of the new company have not been fully disclosed, but it indicates a continuing evolution in the biotech sector, particularly in the realm of mRNA applications. In related news, the FDA has faced criticism for its inconsistent decisions regarding drug approvals, particularly concerning therapies for rare diseases. Recently, the agency rejected an experimental therapy intended to treat a rare blood cancer, despite internal reviewers recommending it for approval. This unexpected decision has raised concerns among drugmakers and advocates for rare diseases, who feel misled by the FDA's mixed signals. Families affected by these conditions have expressed frustration, feeling uncertain about the future of drug approvals for necessary treatments. The implications of the FDA's rejection extend beyond the immediate therapy, affecting the overall landscape for drug approvals targeting rare conditions. Advocates and families are navigating the complexities of securing access to medications, which has been complicated by the FDA's shifting decisions. This situation highlights the ongoing challenges within the pharmaceutical industry, particularly regarding regulatory processes and communication with stakeholders. Additionally, the FDA has issued warning letters to multiple telehealth firms concerning their marketing practices related to compounded GLP-1 medications, reflecting increased scrutiny in this area. This regulatory action underscores the FDA's commitment to ensuring compliance with established standards in telehealth services, which may impact a broader range of stakeholders involved in the marketing and prescribing of GLP-1 drugs. The developments in both the mRNA sector and the FDA's regulatory actions illustrate the dynamic and often contentious nature of the pharmaceutical landscape.